Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DONEPEZIL HCL

All products: not a benefit

Other products in the same Health Canada class (N06DA) — coverage varies; not interchangeable

  • Galantamine (Reminyl ER): limited Use 347, 348, Not a benefit
  • Rivastigmine (Exelon): limited Use 347, 348, Not a benefit

Aricept RDT · DIN 02269465 · 10mg · Orally Disintegrating tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-28 — choose a marketed DIN from the same-category list.Discontinued 2022-10-28 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-10-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Aricept RDT · DIN 02269465 Manufacturer: Pfizer Canada Inc.; listing date 2014-02-27 Health Canada: Cancelled post market since 2022-10-28 · brand ARICEPT RDT · ATC N06DA02 DONEPEZIL · form Tablet (orally-disintegrating) · route Oral · ingredients DONEPEZIL HYDROCHLORIDE 10 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Aricept RDT: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75484 · Verify on the e-Formulary ↗ (DIN 02269465)

Source record
DIN 02269465: Aricept RDT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 120400034; group id 192; item number 0353; lccId None; manufacturer id PFI Source form: Orally Disintegrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02269465 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75484
Interchangeable products
Co Donepezil ODT · DIN 02397625 · not recorded Sandoz Donepezil ODT · DIN 02367696 · not recorded
Shortage status: discontinued (2022-10-01, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02269465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-10-28 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:04 Parasympathomimetic (Cholinergic) Agents) and how they are covered

Matched class: 12:04 Parasympathomimetic (Cholinergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETHANECHOL CHLORIDE, CARBACHOL, PYRIDOSTIGMINE BROMIDE 12:04 Parasympathomimetic (Cholinergic) Agents

GALANTAMINE HYDROBROMIDE

· 18 products · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) · strengths: 8mg, 16mg, 24mg · ER Cap

RIVASTIGMINE

· 34 products · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.5mg, 3mg, 4.5mg, 6mg, 9mg/5 Sq Cm, 18mg/10 Sq Cm · Cap, Trans Patch

BETHANECHOL CHLORIDE

· 3 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CARBACHOL

· 1 products · General benefit · strengths: 2mg · Tab

PYRIDOSTIGMINE BROMIDE

· 4 products · General benefit · strengths: 180mg, 60mg · LA Tab, Tab

PILOCARPINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:04
Full class listing Related classes: 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: dementia of the alzheimers type
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. GALANTAMINE HYDROBROMIDE · Listed, not a benefit (3), Limited Use, codes 347, 348 (15) Indications Galantamine ER (galantamine extended release capsules) is indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer’s type. PM: https://pdf.hres.ca/dpd_pm/00085752.PDF; date 2026-08-11; DIN 02316943; fetched 2026-09-10 Product monograph RIVASTIGMINE · Limited Use, codes 347, 348 (28), Off-Formulary Interchangeable, not an ODB benefit (6) 1 INDICATIONS EXELON® (rivastigmine hydrogen tartrate) is indicated for: • The symptomatic treatment of patients with mild to moderate dementia of the Alzheimer's type. PM: https://pdf.hres.ca/dpd_pm/00085220.PDF; date 2026-07-02; DIN 02242115; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ARICEPT (donepezil hydrochloride) is indicated for: • symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s type. Efficacy of ARICEPT in patients with mild to moderate Alzheimer’s disease was established in two 24 week and one 54-week placebo-controlled trials. Efficacy in patients with severe Alzheimer’s disease was established in three 24-week/6-month placebo-controlled trials. ARICEPT tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Dose escalation in patients > 85 years old should proceed with caution (see 4.1 Dosing Considerations; and 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00077966.PDF PM date: AUG 12, 1997 Source product: ARICEPT; DIN 02232043; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Aricept RDT · DIN 02269465 Shortage status: discontinued (2022-10-01, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02269465

Check this DIN again

Other review policies

For Aricept RDT: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026